Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114710 | 1.00 | OPRK1 (0.48) | OPRK1KCNH2OPRM1GRIN1GRIN2B | |
| SCHEMBL4114703 | 1.00 | OPRK1 (0.48) | OPRK1KCNH2OPRM1GRIN1GRIN2B | |
| SCHEMBL1025315 | 0.89 | OPRK1 (0.43) | OPRK1KCNH2OPRM1GRIN1GRIN2B | |
| SCHEMBL1025314 | 0.89 | OPRK1 (0.43) | OPRK1KCNH2OPRM1GRIN1GRIN2B | |
| SCHEMBL1022974 | 0.82 | SLC6A3 (0.53) | OPRK1KCNH2OPRM1SLC6A2SLC6A3 | |
| SCHEMBL1022975 | 0.82 | SLC6A3 (0.53) | OPRK1KCNH2OPRM1SLC6A2SLC6A3 | |
| SCHEMBL4176415 | 0.82 | SLC6A3 (0.53) | OPRK1KCNH2OPRM1SLC6A2SLC6A3 | |
| SCHEMBL1022408 | 0.81 | OPRM1 (0.45) | OPRK1KCNH2OPRM1GRIN1GRIN2B | |
| SCHEMBL1022409 | 0.81 | OPRM1 (0.45) | OPRK1KCNH2OPRM1GRIN1GRIN2B | |
| SCHEMBL1022406 | 0.81 | OPRM1 (0.45) | OPRK1KCNH2OPRM1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501771-B2 | Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090082391-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082391-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, AHR, MCHR2 | OPRK1 206/4885KCNH2 1583/4885OPRM1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.